17:26 EDT Anixa Biosciences (ANIX) files $200M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating
- Anixa completes dosing of fourth cohort in Phase 1 trial of CAR-T/CER-T therapy
- Anixa receives notice of allowance in China for cancer vaccine technology patent
- Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort
- Anixa Biosciences issued additional U.S. patent for CAR-T technology